Objective: To evaluate the effect of intravitreal Ranibizumab in CSCR with ink blot type of leakage and NSD> 3 months duration. Study Design: Prospective Study. Place and Duration of Study: Base Hospital Delhi Cantt, New Delhi 110010 and Army College of Medical Sciences. Methodology: 20 eyes of 20 adult patients with CSCR were included in the prospective study of duration 08 weeks (02 months). Patients with bilateral CSCR, smoke stack and diffuse leakage of dye on FFA, choroidal neovascularization, treated cases of CSCR, history of thromboembolism, and intraocular inflammation were excluded from the study. After informed consent, all patients were given intravitreal injection of Ranibizumab. Best corrected visual acuity (BCVA) and central macular thickness (CMT) measurement with OCT and pattern of leaks were recorded on FFA at baseline and follow up at 02 and 08 weeks. The outcome measures were mainly BCVA status, CMT on OCT and changes in pattern of leaks on FFA pre and post Anti VEGF. Results: There were 15 (75%) males and 5 (25%) females. All cases were unilateral. Mean age was 39.09 ± 8.49 years. 11 (55%) eyes showed between 3to6 months involvement and 9 (45%) eyes showed more than 6 months involvement. All the cases were treated with single intravitreal dose of 0.5 mg Ranibizumab. After 08 weeks followup, It was observed that the CSCR with ink blot pattern showed moderate visual gain as well as 66.6% decrease in leak intensity on FFA (p <0.001). In addition, mean CMT on OCT showed 70% (p <0.001) decrease at 02 months follow up period. Conclusion: Intravitreal Ranibizumab injection was associated with improvement in BCVA, decrease in intensity as well as delay in onset of ink blot pattern of leaks on FFA and improvement in mean CMT as well as decreased NSD height on OCT in patients of CSCR.

Keywords: Central Serous Chorioretinopathy; Injection Ranibizumab; Optical Coherence Tomography, Intravitreal Injection.